interval. Avoid or Use Alternate Drug.primidoneMonitor Closely (1)primidone increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.procainamideSerious - Use Alternative (1)formoterol and procainamide both increase QTc interval. Avoid or Use Alternate Drug.procarbazineMonitor Closely (1)procarbazine increases effects of formoterol by pharmacodynamic synergism. Use Caution/Monitor.prochlorperazineMonitor Closely (1)prochlorperazine increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.Serious - Use Alternative (1)prochlorperazine and formoterol both increase QTc interval. Avoid or Use Alternate Drug.promazineSerious - Use Alternative (1)promazine and formoterol both increase QTc interval. Avoid or Use Alternate Drug.promethazineMonitor Closely (1)promethazine increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.Serious - Use Alternative (1)promethazine and formoterol both increase QTc interval. Avoid or Use Alternate Drug.propranololMonitor Closely (2)propranolol decreases effects of formoterol by pharmacodynamic antagonism. Use Caution/Monitor. propranolol increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.propylhexedrineMonitor Closely (2)formoterol and propylhexedrine both decrease sedation. Use Caution/Monitor. formoterol and propylhexedrine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.protriptylineMonitor Closely (1)protriptyline increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.Serious - Use Alternative (2)protriptyline and formoterol both increase QTc interval. Avoid or Use Alternate Drug. protriptyline, formoterol. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.pseudoephedrineMonitor Closely (1)formoterol and pseudoephedrine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.quazepamMonitor Closely (1)quazepam increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.quetiapineMonitor Closely (1)quetiapine increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.quinidineSerious - Use Alternative (1)quinidine and formoterol both increase QTc interval. Avoid or Use Alternate Drug.quinineMonitor Closely (1)formoterol and quinine both increase QTc interval. Use Caution/Monitor.ranolazineMonitor Closely (1)formoterol and ranolazine both increase QTc interval. Modify Therapy/Monitor Closely.ribociclibMonitor Closely (1)ribociclib increases toxicity of formoterol by QTc interval. Use Caution/Monitor.risperidoneMonitor Closely (2)formoterol and risperidone both increase QTc interval. Modify Therapy/Monitor Closely. risperidone increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.sacubitril/valsartanMonitor Closely (1)sacubitril/valsartan increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.sageMinor (1)sage increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Minor/Significance Unknown.salicylates (non-asa)Monitor Closely (1)salicylates (non-asa) increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.salmeterolMonitor Closely (3)formoterol and salmeterol both decrease serum potassium. Use Caution/Monitor. formoterol and salmeterol both decrease sedation. Use Caution/Monitor. formoterol and salmeterol both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.salsalateMonitor Closely (1)salsalate increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.scullcapMonitor Closely (1)scullcap increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.secobarbitalMonitor Closely (1)secobarbital increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.selpercatinibMonitor Closely (1)selpercatinib increases toxicity of formoterol by QTc interval. Use Caution/Monitor.serdexmethylphenidate/dexmethylphenidateMonitor Closely (1)formoterol and serdexmethylphenidate/dexmethylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.shepherd's purseMonitor Closely (1)shepherd's purse increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.sodium sulfate/potassium chloride/magnesium sulfate/polyethylene glycolMonitor Closely (1)formoterol and sodium sulfate/potassium chloride/magnesium sulfate/polyethylene glycol both decrease serum potassium. Modify Therapy/Monitor Closely.solriamfetolMonitor Closely (1)formoterol and solriamfetol both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.sorafenibMonitor Closely (1)sorafenib and formoterol both increase QTc interval. Use Caution/Monitor.sotalolMonitor Closely (2)sotalol decreases effects of formoterol by pharmacodynamic antagonism. Use Caution/Monitor. sotalol increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.Serious - Use Alternative (2)formoterol and sotalol both increase QTc interval. Avoid or Use Alternate Drug. Drugs known to prolong the QTc interval may potentiate the cardiovascular effects of formoterol. sotalol and formoterol both increase QTc interval. Avoid or Use Alternate Drug. Drugs known to prolong the QTc interval may potentiate the cardiovascular effects of formoterol.spironolactoneMonitor Closely (1)spironolactone increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.stiripentolMonitor Closely (1)stiripentol will increase the level or effect of budesonide inhaled by P-glycoprotein (MDR1) efflux transporter. Modify Therapy/Monitor Closely. Consider reducing the dose of P-glycoprotein (P-gp) substrates, if adverse reactions are experienced when administered concomitantly with stiripentol.succinylcholineMonitor Closely (1)succinylcholine increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.sufentanilMonitor Closely (1)sufentanil increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.sulfamethoxazoleMonitor Closely (1)sulfamethoxazole and formoterol both increase QTc interval. Modify Therapy/Monitor Closely.sulfasalazineMonitor Closely (1)sulfasalazine increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.sulindacMonitor Closely (1)sulindac increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.tapentadolMonitor Closely (1)tapentadol increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.telavancinMonitor Closely (1)formoterol and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.temazepamMonitor Closely (1)temazepam increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.terbutalineMonitor Closely (3)formoterol and terbutaline both decrease serum potassium. Use Caution/Monitor. formoterol and terbutaline both decrease sedation. Use Caution/Monitor. formoterol and terbutaline both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.thioridazineMonitor Closely (1)thioridazine increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.Serious - Use Alternative (1)thioridazine and formoterol both increase QTc interval. Avoid or Use Alternate Drug.thiothixeneMonitor Closely (1)thiothixene increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.timololMonitor Closely (2)timolol decreases effects of formoterol by pharmacodynamic antagonism. Use Caution/Monitor. timolol increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.tolfenamic acidMonitor Closely (1)tolfenamic acid increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.tolmetinMonitor Closely (1)tolmetin increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.tolvaptanMonitor Closely (1)tolvaptan increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.topiramateMonitor Closely (1)topiramate increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.torsemideMonitor Closely (1)formoterol and torsemide both decrease serum potassium. Use Caution/Monitor.Minor (1)formoterol, torsemide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia.tramadolMonitor Closely (1)tramadol increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.tranylcypromineSerious - Use Alternative (1)tranylcypromine increases effects of formoterol by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.trazodoneMonitor Closely (1)trazodone increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.Serious - Use Alternative (2)trazodone and formoterol both increase QTc interval. Avoid or Use Alternate Drug. trazodone, formoterol. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.triamtereneMonitor Closely (1)triamterene increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.triazolamMonitor Closely (1)triazolam increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.triclofosMonitor Closely (1)triclofos increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.trifluoperazineMonitor Closely (1)trifluoperazine increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.Serious - Use Alternative (1)trifluoperazine and formoterol both increase QTc interval. Avoid or Use Alternate Drug.trimethoprimMonitor Closely (1)formoterol and trimethoprim both increase QTc interval. Modify Therapy/Monitor Closely.trimipramineMonitor Closely (1)trimipramine increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.Serious - Use Alternative (2)trimipramine and formoterol both increase QTc interval. Avoid or Use Alternate Drug. trimipramine, formoterol. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.triprolidineMonitor Closely (1)triprolidine increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.triptorelinMonitor Closely (1)triptorelin increases levels of formoterol by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes.tropisetronMonitor Closely (1)formoterol and tropisetron both increase QTc interval. Modify Therapy/Monitor Closely.umeclidinium bromide/vilanterol inhaledSerious - Use Alternative (1)formoterol increases toxicity of umeclidinium bromide/vilanterol inhaled by QTc interval. Avoid or Use Alternate Drug. Exercise extreme caution when vilanterol coadministered with drugs that prolong QTc interval; adrenergic agonist effects on the cardiovascular system may be potentiated.venlafaxineMonitor Closely (1)formoterol and venlafaxine both increase QTc interval. Modify Therapy/Monitor Closely.vilanterol/fluticasone furoate inhaledSerious - Use Alternative (1)formoterol increases toxicity of vilanterol/fluticasone furoate inhaled by QTc interval. Avoid or Use Alternate Drug. Exercise extreme caution when vilanterol coadministered with drugs that prolong QTc interval; adrenergic agonist effects on the cardiovascular system may be potentiated.voriconazoleMonitor Closely (1)formoterol and voriconazole both increase QTc interval. Modify Therapy/Monitor Closely.xylometazolineMonitor Closely (2)formoterol and xylometazoline both decrease sedation. Use Caution/Monitor. formoterol and xylometazoline both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.yohimbineMonitor Closely (2)formoterol and yohimbine both decrease sedation. Use Caution/Monitor. formoterol and yohimbine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.ziconotideMonitor Closely (1)ziconotide increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.ziprasidoneMonitor Closely (1)ziprasidone increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.Serious - Use Alternative (1)formoterol and ziprasidone both increase QTc interval. Avoid or Use Alternate Drug. >10% Upper respiratory tract infection (URTI) (8-11%) Headache (7-11%) Nasopharyngitis (7-11%) 1-10% Pharyngolaryngeal pain (6-9%) Stomach discomfort (1-7%) Sinusitis (5-6%) Oral candidiasis (1-6%) Bronchitis (5%) Viral URTI (4%) Backache (2-3%) Influenza (2-3%) Nasal congestion (2-3%) Vomiting (1- 3%) Postmarketing Reports Cardiovascular: Angina pectoris, tachycardia, atrial and ventricular tachyarrhythmias, atrial fibrillation, extrasystoles, palpitations, hypotension, hypertension Endocrine: Hypercorticism, growth velocity reduction (in children) Sensory: Cataract, glaucoma, increased intraocular pressure (IOP), skin bruising Gastrointestinal (GI): Oropharyngeal candidiasis, nausea Immunologic: Immediate and delayed hypersensitivity reactions, such as anaphylactic reaction, angioedema, bronchospasm, urticaria, exanthema, dermatitis, pruritus Metabolic: Hyperglycemia, hypokalemia Musculoskeletal: Muscle cramps Neurologic and psychiatric: Behavior disturbances, sleep disturbances, nervousness, agitation, depression, restlessness tremor, dizziness Respiratory: Dysphonia, cough, throat irritation Contraindications Hypersensitivity Primary treatment of status asthmaticus or acute episodes of asthma or COPD requiring intensive measures Cautions Risk of LABAs used as monotherapy Use of LABAs as monotherapy (without inhaled corticosteroids) for asthma is associated with an increased risk of asthma-related death Data from controlled clinical trials also suggest that use of LABA as monotherapy increases the risk of asthma-related hospitalization in pediatric and adolescent patient These findings are considered a class effect of LABA monotherapy When LABA are used in fixed-dose combination with ICS, data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared with ICS alone Do not initiate in patients experiencing rapidly deteriorating or potentially life-threatening asthma or COPD episodes; additionally, increased inhaled SABA use is marker of deteriorating asthma Do not use for relief of acute symptoms (rescue therapy) Maximum dosage must not be exceeded, because of increased risk of serious cardiovascular effects Localized infections with Candida albicans in mouth and pharynx occur in some patients; to reduce risk, mouth must be rinsed after inhalation Monitor COPD patients for signs and symptoms of pneumonia and lung infections Risk of more serious or fatal course of chickenpox or measles exists in susceptible patients (eg, unvaccinated or immunologically unexposed individuals); care must be taken to avoid exposure Excessive use may suppress hypothalamic-pituitary-adrenal function; monitor closely, especially postoperatively or during periods of stress During periods of stress, a severe asthma attack or a severe COPD exacerbation, patients who have been withdrawn from systemic corticosteroids should be instructed to resume oral corticosteroids (in large doses) immediately and to contact their physicians for further instruction Risk of paradoxical bronchospasm, which may be life-threatening; discontinue and treat immediately with inhaled SABA Risk of immediate hypersensitivity reactions (eg, urticaria, angioedema, rash, bronchospasm) Cardiovascular and central nervous system (CNS) effects due to excess beta-adrenergic stimulation; may result in asthma-related death; use with caution in patients with cardiovascular or convulsive disorders or thyrotoxicosis Particular care is needed to transfer patients from